ARTICLE | Clinical News
Omarigliptin: Phase III data
September 21, 2015 7:00 AM UTC
A double-blind Phase III trial in 642 Type II diabetics inadequately controlled on metformin showed that once-weekly 25 mg omarigliptin as an add-on to metformin met the primary endpoint of non-inferi...